ArticleJournal of cardiothoracic surgery2025
Drug-coated balloon angioplasty for catastrophic left main STEMI in a 24-year-old with antiphospholipid syndrome: a case report.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antiphospholipid syndrome (APS), characterized by antiphospholipid antibody (aPL)-driven thrombosis, is increasingly recognized as a critical etiology of catastrophic coronary events in young adults lacking traditional cardiovascular risk factors. This report delineates a 24-year-old male with left main coronary artery (LMCA) ST-segment elevation myocardial infarction (STEMI), managed through a novel strategy combining drug-coated balloon (DCB) angioplasty and APS-targeted pharmacotherapy (anticoagulation and immunomodulation). The case underscores the necessity of etiological exploration in young STEMI populations and challenges the conventional stent-based revascularization paradigm in hypercoagulable states. One-year follow-up demonstrated sustained patency without recurrent thrombosis, validating the efficacy of pathophysiology-guided interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.